NATICK, Mass.--(BUSINESS WIRE)--AffyImmune Therapeutics, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, today announced that Matt Britz, President, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on February 29, 2024..

马萨诸塞州纳蒂克市。-（商业新闻短讯）--AffyiImmune Therapeutics是一家临床阶段的生物制药公司，致力于开发新型，一流，亲和力调节的CAR T细胞疗法，今天宣布，总裁马特·布里茨将参加2024年2月29日在Evercore ISI 2024 Emerging Biotech大会上的虚拟炉边聊天。。

The discussion will be available via a listen-only live webcast accessible at https://wsw.com/webcast/evercore40/affyi/2535793. The webcast will be available for replay at https://affyimmune.com/news/ starting March 4, 2024, and will remain archived following the conference.

讨论将通过在线直播进行，网址为https://wsw.com/webcast/evercore40/affyi/2535793.网络广播将在https://affyimmune.com/news/从2024年3月4日开始，并将在会议后继续存档。

About AffyImmune Therapeutics

关于AffyiImmune Therapeutics

AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR-T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM1/LFA-1 interaction can potentially address all critical CAR-T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR-T cells.

AffyiImmune是一家临床阶段的生物制药公司，致力于开发新型，一流的亲和力调节的CAR-T细胞疗法，以改变癌症患者的生活。该公司利用ICAM1/LFA-1相互作用的专有技术可以潜在地解决所有关键的CAR-T挑战，例如毒性，抗原损失，T细胞运输和衰竭，同时还允许体内追踪CAR-T细胞。

Its lead candidate, AIC100, is a ICAM1-directed CAR-T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com..

其主要候选药物AIC100是针对晚期甲状腺癌患者开发的ICAM1指导的CAR-T疗法。AffyImmune正在开发一种针对ICAM-1的治疗药物，用于未满足医疗需求的肿瘤适应症。AffyImmune位于马萨诸塞州纳蒂克。有关更多信息，请访问www.AffyImmune.com。。